WallStreetZenWallStreetZen

NASDAQ: TVTX
Travere Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Travere Therapeutics earnings were -$88.5M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. The latest TVTX earnings report on Sep 30, 2025 announced Q3 2025 earnings of $25.7M, down 301.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TVTX reported annual earnings of -$321.5M, with 188.6% growth.

TVTX earnings history

Current Revenue
$435.8M
Current Earnings
-$88.5M
Current Profit Margin
-20.3%

TVTX Return on Equity

Current Company
-178.7%
Current Industry
-21.3%
Current Market
35.2%
TVTX's Return on Equity (-178.7%)... subscribe to Premium to read more.
High Return on Equity Performance

TVTX undefined

Current Company
-15.8%
Current Industry
-8.8%
TVTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when TVTX announces earnings.

TVTX undefined

Current Company
-19.15%
Current Industry
-3.4%
TVTX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

TVTX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
TVTX-$22.58M-$88.54MN/A-$1.03
OCUL-$233.54M-$249.67MN/A-$1.43
VRDN-$299.04M-$301.97MN/A-$2.30
KNSA$53.58M$35.92M-91.34%$0.49
VERA-$242.17M-$251.94MN/A-$3.99
View Top Biotech Stocks

Travere Therapeutics Earnings Reports & History FAQ

What were Travere Therapeutics's earnings last quarter?

On TVTX's earnings call on Invalid Date, Travere Therapeutics (NASDAQ: TVTX) reported Q3 2025 earnings per share (EPS) of $0.29, up 141.43% year over year. Total TVTX earnings for the quarter were $25.71 million. In the same quarter last year, Travere Therapeutics's earnings per share (EPS) was -$0.70.

If you're new to stock investing, here's how to buy Travere Therapeutics stock.

Is Travere Therapeutics profitable or losing money?

As of the last Travere Therapeutics earnings report, Travere Therapeutics is currently losing money. Travere Therapeutics's net profit (also called net income) for the twelve months ending Sep 30, 2025 was -$88.54 million, a 74.81% decrease year over year.

What was TVTX's earnings growth in the past year?

As of Travere Therapeutics's earnings date in Invalid Date, Travere Therapeutics's earnings has grown year over year. TVTX earnings in the past year totalled -$88.54 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.